1. High-sensitivity C-reactive protein and risk of clinical outcomes in patients with acute heart failure
- Author
-
Enrique Santas, Sandra Villar, Patricia Palau, Pau Llàcer, Rafael de la Espriella, Gema Miñana, Miguel Lorenzo, Gonzalo Núñez-Marín, Jose Luis Górriz, Arturo Carratalá, Enrique Rodríguez, Antoni Bayes-Genís, Juan Sanchis, and Julio Núñez
- Subjects
Heart failure ,C-reactive protein ,Inflammation ,Prognosis ,Mortality ,Hospitalizations ,Medicine ,Science - Abstract
Abstract Inflammation is relevant in the pathogenesis and progression of heart failure (HF). Previous studies have shown that elevated high-sensitivity C-reactive protein (hsCRP) are associated with greater severity and may be associated with adverse outcomes. In this study, we sought to evaluate the prognostic role of hsCRP in a non-selected cohort of patients with acute HF. We prospectively included a multicenter cohort of 3,395 patients following an admission for acute HF. HsCRP levels were evaluated during the first 24 h following admission. Study endpoints were the risks of all-cause mortality, CV-mortality, and total HF readmissions. The mean age was 74.2 ± 11.2 years and 1,826 (53.8%) showed a left ventricular ejection fraction (LVEF) ≥ 50%. Median hsCRP was 12.9 mg/L (5.4–30 mg/L). Over a median follow-up of 1.8 (0.6–4.1) years, 1,574 (46.4%) patients died, and 1,341 (39.5%) patients were readmitted for worsening HF. After multivariable adjustment, hsCRP values were significantly and positively associated with a higher risk of all-cause and CV mortality (p = 0.003 and p = 0.001, respectively), as well as a higher risk of recurrent HF admissions (p
- Published
- 2024
- Full Text
- View/download PDF